Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Josep‐María Ribera(Universitat Autònoma de Barcelona), James McCloskey(Hackensack University Medical Center), Vanderson Rocha(Fundação Pró-Sangue Hemocentro de São Paulo), Jessica Leonard(Oregon Health & Science University), Carlo Gambacorti‐Passerini(Azienda Ospedaliera San Gerardo), Pankit Vachhani(University of Alabama at Birmingham), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Ibrahim Aldoss(City of Hope), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Maria R. Baer(University of Maryland, Baltimore), Alexander Vorog(Takeda (United States)), Philippe Rousselot(Université Paris-Saclay), Niti Patel(Takeda (United States)), Yosuke Minami(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Bingxia Wang(Takeda (United States)), Meliessa Hennessy(Takeda (United States)), David Gómez‐Almaguer(Universidad Autónoma de Nuevo León), Tammie C. Yeh(Stanford University), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 119
Related Papers
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k